Viral RNA isolation for COVID-19 research
We offer an assortment of kits that enable efficient isolation of viral nucleic acids from clinical samples such as nasopharyngeal and oropharyngeal swabs, sputum, and other bodily fluids. For applications relevant to the study of the novel coronavirus responsible for COVID-19 disease, we recommend NucleoSpin RNA Virus, NucleoMag Pathogen, and NucleoSpin 8/96 Virus. Click “More” for additional information.
We offer an assortment of kits that enable efficient isolation of viral nucleic acids from clinical samples such as nasopharyngeal and oropharyngeal swabs, sputum, and other bodily fluids. For applications relevant to the study of the novel coronavirus responsible for COVID-19 disease, we recommend the following:
- NucleoSpin RNA Virus: silica membrane purification of viral RNA using a simple mini spin column-based protocol that can be completed in ~30 min. This product is comparable to the QIAamp Viral RNA Mini Kit from Qiagen and is already being employed in SARS-CoV-2-related studies around the world.
- NucleoMag Pathogen: high-throughput isolation of viral nucleic acids using scalable, automation-friendly magnetic beads. Scripts available for many common automation platforms.*
- NucleoSpin 8/96 Virus: high-throughput isolation of viral nucleic acids using silica membrane technology in 8- or 96-well formats. These kits can be used for manual or automated sample processing, with scripts available for many common automation platforms.*
*To obtain automation scripts, please send an email to technical_support@takarabio.com with the following information: kit name, automation platform model, software version.
More Information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Find more products for COVID-19 research
Helping researchers tackle COVID-19
Know your enemy: finding certainty in uncertain times
This blog highlights one of the first studies identifying and characterizing the novel coronavirus, ultimately contributing to the viral genome sequence being shared worldwide.
Screening for the novel coronavirus with one-step RT-qPCR
Learn how researchers identified a novel, highly contagious coronavirus and developed a one-step RT-qPCR screening protocol.
Entering new worlds while staying in place
Hear how a Product Manager in Europe is adjusting to the changing research market in light of COVID-19.
Working hard to meet production demands for SARS-CoV-2 testing
Hear how a Takara Bio employee of 27 years is contributing to the COVID-19 effort.
Dethroning king coronavirus with novel vaccines
Find out which types of SARS-CoV-2 vaccines are out there and how Takara Bio is joining the fight.
COVID-19 drug discovery
Our hiPSC-derived cells and other cell biology research products help you study SARS-CoV-2 infection, identify potential targets for drug discovery, evaluate the metabolism and safety of candidate drugs, and develop therapeutic approaches for COVID-19.
Takara Bio products in COVID-19 publications
An ever-growing compilation of COVID-19 publications using Takara Bio products and technologies.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2026 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
